Sponsor or institution

Clinical trials and research at Princess Maxima Center for Pediatric Oncology

• 11Clinical trials
• 26Countries

Newest trials

All recruiting trials (11)

• Anti-GD2-800CW imaging to highlight neuroblastoma during surgery

  This trial will test whether a fluorescent antibody called anti-GD2-800CW can safely help surgeons see and remove neuroblastoma in children ages 1 to 18.

  Recruiting Phase 1/2 Princess Maxima Center for Pediatric Oncology · Utrecht · NCT07399821

• Vyxeos plus clofarabine for relapsed or refractory pediatric AML

  This trial tries combining Vyxeos (liposomal daunorubicin/cytarabine) with clofarabine to treat children and young adults aged 1–21 with relapsed or refractory AML.

  Recruiting at 13 sites Phase 1 Princess Maxima Center for Pediatric Oncology · Vienna and 12 other locations · NCT07156435

• Dinutuximab beta combined with two induction chemotherapy regimens for newly diagnosed high-risk neuroblastoma

  This will test different doses of dinutuximab beta given with two standard induction chemotherapy regimens in children (18 months to under 18 years) with newly diagnosed high‑risk neuroblastoma to find a safe recommended dose.

  Recruiting Phase 1 Princess Maxima Center for Pediatric Oncology · Utrecht, Utrecht · NCT06485947

• Combining Quizartinib with Chemotherapy for Pediatric AML Patients

  This study is testing if adding a new drug called quizartinib to standard chemotherapy can help children with a specific type of leukemia feel better and have better treatment outcomes.

  Recruiting Phase 2 Princess Maxima Center for Pediatric Oncology · Utrecht, Utrecht · NCT06262438

• Improving treatment for newly diagnosed pediatric acute myeloid leukemia

  This study is testing new ways to treat children with newly diagnosed acute myeloid leukemia to help them get better while reducing the side effects of treatment.

  Recruiting Phase 3 Princess Maxima Center for Pediatric Oncology · Utrecht, Utrecht · NCT05994690

• Dasatinib and venetoclax with dexamethasone, cyclophosphamide, and cytarabine for children and young adults with relapsed or refractory ALL/LBL with MAPK/SRC changes

  This treatment tests whether adding dasatinib and venetoclax to dexamethasone, cyclophosphamide, and cytarabine helps children and young people (up to 21) whose relapsed or refractory acute lymphoblastic leukemia or lymphoblastic lymphoma have specific MAPK/SRC pathway changes.

  Recruiting at 2 sites Phase 1/2 Princess Maxima Center for Pediatric Oncology · Vienna and 32 other locations · NCT05751044

• Ruxolitinib and venetoclax added to chemotherapy for children and young adults with relapsed or refractory ALL/LBL

  This trial tests whether adding ruxolitinib and venetoclax to dexamethasone, cyclophosphamide and cytarabine helps children and young adults with relapsed or refractory acute lymphoblastic leukemia or lymphoblastic lymphoma who have IL7R/JAK-STAT pathway changes.

  Recruiting at 3 sites Phase 1/2 Princess Maxima Center for Pediatric Oncology · Vienna and 32 other locations · NCT05745714

• Combination treatment for children with relapsed or refractory blood cancers

  This study is testing a new combination of medications to see if it can help children and young adults with tough-to-treat blood cancers feel better and improve their chances of recovery.

  Recruiting at 5 sites Phase 1/2 Princess Maxima Center for Pediatric Oncology · Vienna and 35 other locations · NCT05658640

• Treatment for infants with specific types of leukemia

  This study is testing a new treatment using blinatumomab for infants with specific types of leukemia to see if it can help them respond better to therapy.

  Recruiting at 101 sites Phase 3 Princess Maxima Center for Pediatric Oncology · Buenos Aires and 123 other locations · NCT05327894

• International Leukemia Target Board for children with relapsed hematologic malignancies

  This study is trying to find the best treatment options for children with relapsed blood cancers by looking at their unique disease characteristics and how they respond to different drugs.

  Recruiting at 7 sites Princess Maxima Center for Pediatric Oncology · Ghent and 6 other locations · NCT05270096

• Brigatinib treatment for young patients with specific cancers

  This study is testing the right dose of brigatinib to see if it can help young patients with certain types of cancers, like ALK-positive anaplastic large cell lymphoma and inflammatory myofibroblastic tumors.

  Recruiting at 2 sites Phase 1/2 Princess Maxima Center for Pediatric Oncology · Paris and 1 other locations · NCT04925609

Quick answers

How many clinical trials run by Princess Maxima Center for Pediatric Oncology are recruiting right now?

11, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 26 countries. The most sites are in Netherlands (11 trials), Denmark (6 trials), Spain (6 trials), France (5 trials), Austria (5 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1/2: 5, Phase 1: 2, Phase 3: 2, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →